A phase II trial of lapatinib and capecitabine for patients with refractory advanced colorectal adenocarcinoma (LAP109859).

Trial Profile

A phase II trial of lapatinib and capecitabine for patients with refractory advanced colorectal adenocarcinoma (LAP109859).

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2016

At a glance

  • Drugs Capecitabine; Lapatinib
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 May 2010 Actual patient number (29) added as reported by ClinicalTrials.gov.
    • 21 May 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 21 May 2010 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top